Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Careium AB is a prominent player in the telecare sector, focusing on designing and providing technology-enabled care solutions to enhance the quality of life for individuals, particularly the elderly and those with special needs. As a significant contributor in the healthcare technology field, Careium AB develops products that range from personal alarms and communication devices to comprehensive telehealth systems. These solutions are pivotal in ensuring the safety, independence, and well-being of vulnerable populations, and they facilitate real-time monitoring and support services. Careium AB's offerings are critical to healthcare providers, government agencies, and private care institutions, allowing for integrated care approaches that optimize resource use while ensuring high standards of service. In the broader market context, Careium AB plays a vital role in the ongoing transformation of healthcare, from traditional models to more agile and technology-driven solutions, addressing the pressing demand for innovative and sustainable care options.
kr 2.22
+kr 0.00 (+0.00%)
EOD Jun 23, 2026 · Twelve Data
Operating margin is thin at 5.77%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue declined 1.9% YoY. Margins deteriorated 3.9pp alongside, both lines moving the wrong way.
ROIC dropped from 7.84% to 5.58%, capital efficiency is deteriorating. Operating margin contracted 3.9pp YoY, cost discipline may be slipping.
1.6x earnings, 1.3x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 866M
▼ -1.9% YoY
Net Income (TTM)
kr 37M
▼ -41.8% YoY
Op. Margin
5.21%
▼ -3.9pp YoY
ROIC
5.58%
▼ -2.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 41M
▲ +39.0% YoY
Op. Cash Flow (TTM)
kr 94M
▲ +56.4% YoY
Net Debt
kr 155M
Cash & Equiv.
kr 55M
3Y CAGR: +5.6%
Continue Research
At a P/E of 1.6 and a price-to-free-cash-flow of 1.3, Careium AB (CARE.XSTO) trades below a two-stage DCF intrinsic value of about SEK 22.63 per share, so at SEK 2.22 the stock looks undervalued (919.4% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Careium AB scores 56/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 22.63 per share for CARE.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 16.97. At today's SEK 2.22, that puts the stock about 919.4% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Careium AB scores 56 out of 100 on Intrinsiqq's quality score, passing 3 of 8 checks, which makes it a mixed business on these measures. Recent fundamentals include a 5.2% operating margin and a 5.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. CARE.XSTO currently trades below its estimated intrinsic value and scores 56/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.